Perspective Therapeutics announces leadership team will meet investors at upcoming conferences to discuss cancer treatment advancements.
Quiver AI Summary
Perspective Therapeutics, Inc., a company focused on developing radiopharmaceuticals for cancer treatment, announced participation in two upcoming investor conferences. Members of its senior leadership team will hold one-on-one meetings at the Truist Securities BioPharma Symposium on November 6, 2025, in New York, and will participate in a fireside chat at the UBS Global Healthcare Conference on November 11, 2025, in Palm Beach, Florida. The company specializes in utilizing the alpha-emitting isotope 212Pb to target cancer cells effectively while developing imaging diagnostics for personalized treatment. Its current programs include treatments for neuroendocrine tumors, melanoma, and solid tumors, all in Phase 1/2a clinical trials. Additionally, Perspective is expanding its network of facilities for producing drug candidates for clinical trials and commercial use. The press release also includes a safe harbor statement regarding forward-looking statements and associated risks.
Potential Positives
- Perspective Therapeutics is participating in notable investor conferences, enhancing visibility and engagement with potential investors.
- The company is advancing its proprietary technology for targeted cancer treatments, potentially leading to improved patient outcomes.
- Perspective Therapeutics is developing a "theranostic" approach, combining diagnosis and treatment to optimize patient care.
- The company is expanding its network of drug product candidate finishing facilities, which may facilitate faster delivery of treatments to clinical trials and commercial operations.
Potential Negatives
- The press release contains a significant number of forward-looking statements, raising concerns about potential risks and uncertainties that could materially affect the company's actual results.
- There is no concrete update on the progress or outcomes of the ongoing clinical trials for the company's key products, which could lead to investor concerns about the efficacy and commercialization timeline of its therapies.
- The absence of detailed financial information or funding updates may lead to investor apprehension regarding the company's financial stability and its ability to support ongoing and future projects.
FAQ
What is Perspective Therapeutics, Inc. known for?
Perspective Therapeutics, Inc. specializes in radiopharmaceutical development and pioneering advanced cancer treatments using the alpha-emitting isotope 212Pb.
When and where are the upcoming investor conferences?
Upcoming conferences include the Truist Securities BioPharma Symposium on November 6, 2025, in New York, and the UBS Global Healthcare Conference on November 11, 2025, in Palm Beach.
What is the 'theranostic' approach in cancer treatment?
The 'theranostic' approach combines therapy and diagnostic imaging to personalize cancer treatment, improving efficacy while minimizing toxicity.
What types of cancer therapies is Perspective developing?
The Company is developing therapies for neuroendocrine tumors, melanoma, and solid tumors, currently in Phase 1/2a trials in the U.S.
How can I contact Perspective Therapeutics for investor relations?
You can contact Annie J. Cheng, CFA, at [email protected] for investor relations inquiries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CATX Hedge Fund Activity
We have seen 4 institutional investors add shares of $CATX stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTOR CAPITAL, LLC removed 973,619 shares (-99.9%) from their portfolio in Q2 2025, for an estimated $3,349,249
- PORTLAND INVESTMENT COUNSEL INC. added 60,000 shares (+31.6%) to their portfolio in Q2 2025, for an estimated $206,400
- SG AMERICAS SECURITIES, LLC added 13,538 shares (+inf%) to their portfolio in Q3 2025, for an estimated $46,435
- WEALTHPLAN INVESTMENT MANAGEMENT, LLC added 3,022 shares (+0.8%) to their portfolio in Q3 2025, for an estimated $10,365
- WEALTH EFFECTS LLC added 2,000 shares (+8.3%) to their portfolio in Q3 2025, for an estimated $6,860
- CITIZENS FINANCIAL GROUP INC/RI added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- TRUEBLOOD WEALTH MANAGEMENT, LLC added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CATX Analyst Ratings
Wall Street analysts have issued reports on $CATX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 10/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/03/2025
- B. Riley Securities issued a "Buy" rating on 06/23/2025
- Wedbush issued a "Outperform" rating on 06/23/2025
- RBC Capital issued a "Outperform" rating on 06/03/2025
- Truist Securities issued a "Buy" rating on 05/14/2025
To track analyst ratings and price targets for $CATX, check out Quiver Quantitative's $CATX forecast page.
$CATX Price Targets
Multiple analysts have issued price targets for $CATX recently. We have seen 6 analysts offer price targets for $CATX in the last 6 months, with a median target of $11.5.
Here are some recent targets:
- Jeet Mukherjee from BTIG set a target price of $14.0 on 10/13/2025
- Robert Burns from HC Wainwright & Co. set a target price of $10.0 on 10/03/2025
- Yuan Zhi from B. Riley Securities set a target price of $12.0 on 06/23/2025
- David Nierengarten from Wedbush set a target price of $11.0 on 06/23/2025
- Leonid Timashev from RBC Capital set a target price of $16.0 on 06/03/2025
- Nicole Germino from Truist Securities set a target price of $8.0 on 05/14/2025
Full Release
SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:
Truist Securities BioPharma Symposium – 1x1 only
Date:
Thursday, November 6, 2025
Location
: New York, NY
UBS Global Healthcare Conference – Fireside Chat
Date:
Tuesday, November 11, 2025
Time:
4:15- 4:50 p.m. ET
Location:
Palm Beach, FL
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com .
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company’s prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product candidate finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
[email protected]
Russo Partners, LLC
Nic Johnson
[email protected]
